



**PIPER MARBURY
RUDNICK & WOLFE^{LLP}**
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

DOCKET NO.: 9491-043-27 DIV

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Re: Serial No.: 09/610,152
Applicant(s): NAPOLEONE FERRARA, ET AL.
Filing Date: JULY 5, 2000
For: IMPROVED ANGIOGENESIS USING HEPATOCYTE GROWTH
FACTOR
Group Art Unit: 1651
Examiner: WEBER J.

SIR:

Attached hereto for filing are the following papers:

AMENDMENT AFTER FINAL INCLUDING ATTACHMENT
CITED DOCUMENT (1)

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


PIPER MARBURY RUDNICK & WOLFE LLP

2-25-02

Date

Steven B. Kelber
Attorney of Record
Registration No.: 30,073

Amy L. Miller
Registration No.: 43,804



Docket No. 0491-043-27 DIV

TECH CENTER 1600/2900

FEB 27 2002

RECEIVED

#90/02
02-27-02
(NFE)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: NAPOLEONE FERRARA, ET AL. GAU:

SERIAL NO: 09/610,152

EXAMINER: WEBER, J.

FILING DATE: JULY 5, 2000

FOR: IMPROVED ANGIOGENESIS USING HEPATOCYTE GROWTH FACTOR

AMENDMENT AFTER FINAL

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

This Amendment is submitted in answer to the Office Action dated November 26, 2001, which set a three month period for response. Thus, this Amendment is considered timely filed on or before February 26, 2002.

IN THE CLAIMS:

8. (Twice Amended) An article of manufacture, comprising:
a container; and
a composition comprising an active agent contained within said container;
wherein the composition is effective for treating vascular insufficiency or limb ischemia secondary to arterial occlusive disease when administered intravenously, intraarterially, or via infusion, and the active agent in said composition comprises HGF.

10. (Twice Amended) A kit, comprising:
a first container, and a composition comprising an active agent contained within said container;